Sign up for Vip Text Alerts. Text  DEJAVU to 55678 

Get exclusive offers and earn money-saving rewards by joining Deja Vu's VIP Access! Simply text DEJAVU to 55678  on your mobile phone to join and be sure to check-in at kiosk when you visit Deja Vu. Text & data rates may apply."

812-490-SKIN (7546)  

4943 Rosebud Lane

Newburgh, IN 47630

Hours: Monday - Friday

8:00 am - 5:00 pm

  • Facebook Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon
  • instagram

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

Important Safety Information

KYBELLA® is contraindicated in the presence of infection at the injection sites.

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema,and induration.

Report side effects to the FDA at 1-800-FDA-1088 or Allergan Medical Information at 800-433-8871.

Kybella®

Kybella is the first and only FDA-approved injectable treatment to improve the appearance of moderate to severe fat beneath the chin, also known as submental fat, by physically destroying fat cells.

The Science

Kybella is injected into the fat beneath the chin and destroys fat cells. Once these fat cells are destroyed, those cells cannot store or accumulate fat. The active ingredient in Kybella is deoxycholic acid, a naturally occurring molecule in the body that helps in the breakdown and absorption of dietary fat. The destroyed fat from the treatment area is processed through the body’s natural metabolism.

Once the injectable treatment sessions have been completed and the aesthetic effect is achieved, further treatment with Kybella is not expected.